글로벌 처방 디지털 치료제(PDTx) 시장 – 2030년까지의 산업 동향 및 예측

처방 디지털 치료(PDTx) 시장 분석 및 규모

PDTx를 공급자가 수용하는 것은 지불자가 의사에게 디지털 의학에 대한 공정한 보상을 기꺼이 하는 데 달려 있으며, PDTx의 성공에 중요합니다. Pear Therapeutics와 Avalere의 공동 여론 조사에 따르면 지불자의 40%만이 2021년에 PDTx를 보장할 것으로 예상되었으며, 그 중 50%는 향후 18개월 동안 보장할 계획이었습니다. 가장 중요한 요소는 환자 결과를 개선하는 데 있어 PDTx의 임상적 효과입니다. 최근 PDTx에 대한 규제 및 FDA 승인이 급증하고 대부분의 지불자가 미래에 PDTx 환불을 기꺼이 지원하려는 상황에서 혁신을 계속하는 PDTx 생산자에게는 안심이 됩니다.

Data Bridge Market Research는 2022년에 39억 달러 규모였던 처방 디지털 치료제(PDTx) 시장이 2030년까지 171억 6천만 달러에 도달할 것으로 분석했으며, 2023년부터 2030년까지의 예측 기간 동안 연평균 성장률은 20.35%에 이를 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함됩니다.

처방 디지털 치료제(PDTx) 시장 범위 및 세분화      

시장 정의

처방 디지털 치료제는 광범위한 질병을 치료하는 데 사용되는 소프트웨어 기반 치료제의 한 형태입니다. 기술과 생물학이 결합되어 처방 디지털 약물이 만들어집니다. 이러한 치료 도구는 인공 지능 , 여러 알고리즘 및 가상 현실 을 사용하여 만들어졌습니다 . 처방 PDT 또는 디지털 치료제는 완전히 새로운 의학적 범주입니다. PDT는 기존 생물학 또는 약물과 같은 중요한 장애에 대한 직접적인 치료법으로 작용합니다.

처방 디지털 치료제(PDTx) 시장 역학

운전자

• 만성질환 유병률 증가로 성장 촉진

A significant element influencing the prescription digital therapeutics (PDTx) market's growth rate over the forecast period of 2022–2029 is the rising prevalence of chronic disorders. 463 million persons would develop diabetes in 2020, according to the World Health Organization (WHO). By 2045, it is expected that there will be approximately 629 million diabetics globally.

• Rising uses of DTx will drive the market growth

The healthcare sector's pursuit of value-based care, virtual care and tailored treatment will be accelerated by DTx. By administering interactive, personalized therapy at the patient's leisure, these systems enable providers to provide patient-centric care. This can enhance patient satisfaction, which can enhance treatment adherence and health outcomes while reducing unnecessary administrative burdens on healthcare providers.

Opportunities

• Strong pipeline of potential products is a promising opportunity

Prescription digital therapeutics (PDTx) market growth will benefit from the vast pipeline of prospective products expected to be published over the course of the forecast period. Phase III potential Pear Therapeutics clinical therapeutics products include Pear-011 (anxiety GAD), Pear-015 (depression MDD), which are used to treat adults with chronic insomnia and depression, and CT-152 (major depressive disorder) and CT-155 (schizophrenia), which are used to treat adults with schizophrenia and depression. As a result, it is projected that a number of late-stage medications in development will offer promising opportunities for the growth of the prescription digital therapeutics market.

Restraints/Challenges

• Privacy and security will hinder the market growth

Given the strict regulatory restrictions surrounding PHI (Personal Health Information) data, all parties participating in the manufacture and application of digital medicines must work to protect the confidentiality and security of the information gathered. To protect the privacy of patient data, for instance, manufacturers are required to abide by HIPAA (Health Insurance Portability and Accountability Act) rules. To ensure regulatory compliance of data flows, manufacturers must also cooperate with partners who are HITRUST- (Health Information Trust Alliance) certified. This delays the process which will derail the market growth rate.

This prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Reset prescription digital therapies have announced market approval from Singapore's Health Science Authority for the treatment of people with substance use disorders, according to Pear Therapeutics, Inc.

Global Prescription Digital Therapeutics (PDTx) Market Scope

The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application and patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mechanism

• Input Mechanisms
• Output Mechanisms

Category

• Medication Augmentation
• Medication Replacement

Treatment

• Outpatient Treatment
• Monotherapy

Software

• Software for Respiratory Conditions
• Software for Mental Health
• Software for Opioid Use Disorder
• Software for Diabetes
• Others

Services

• Behavioral Microservices
• Medical Microservices

App Accessibility

• Android
• iOS
• Windows

App Type

• Native Apps
• Web Apps

Application

• Substance Use Disorder (SUD)
• Opioid Use Disorder (OUD)
• Attention Deficit/Hyperactivity Disorder (ADHD)
• Alzheimer’s Disease
• Major Depressive Disorder (MDD)
• Insomnia
• Epilepsy
• Movement Disorder
• Multiple Sclerosis
• Migraine
• Autism Spectrum Disorder
• Oncology
• Inflammation
• Respiratory
• Cardiovascular
• Pain Management
• Metabolic Conditions
• Others

Patients

• Children
• Adults

Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights

The prescription digital therapeutics (PDTx) market is analysed and market size insights and trends are provided by country, mechanism, category, treatment, software, services, app accessibility, app type, application and patients as referenced above.

The countries covered in the prescription digital therapeutics (PDTx) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prescription digital therapeutics (PDTx) market due to increased research and development being done on prescription digital therapeutics (PDTx) and rising healthcare spending. The expansion of the main companies and the entrance of new start-ups will also accelerate the market's growth rate in this area.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to rising healthcare costs and the region's growing prevalence of chronic diseases. Additionally, improvements in the system for paying for digital therapies may speed up the market's expansion in this area.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Prescription Digital Therapeutics (PDTx) Market Share Analysis

The prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prescription digital therapeutics (PDTx) market.

Some of the major players operating in the prescription digital therapeutics (PDTx) market are:

• ResMed (U.S.)
• SAMSUNGHEALTHCARE (South Korea)
• Biofourmis (US)
• Novartis AG (Switzerland)
• Medtronic (Ireland)
• Pear Therapeutics, Inc. (U.S.)
• Voluntis (France)
• Omada Health, Inc. (U.S.)
• GAIA AG (Germany)
• Welldoc’s Bluestar (U.S.)
• Solera Network (U.S.)
• Akili Interactive Labs, Inc. (U.S.)
• Better Therapeutics, LLC (U.S.)
• 빅헬스(미국)
• 바이오푸르미스(미국)
• 클릭 테라퓨틱스 주식회사(미국)
• 해피파이 주식회사(미국)
• 림빅스 헬스(Limbix Health, Inc.) (미국)
• Naturalcycles Nordic AB(스웨덴)
• NuvoAir AB(스웨덴)
• Sensyne Health plc. (영국)
• Xealth (미국)

SKU-46333